Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
After finishing at $6.91 in the prior trading day, Abeona Therapeutics Inc (NASDAQ: ABEO) closed at $6.84, down -1.01%. In other words, the price has decreased by -$1.01 from its previous closing price. On the day, 0.86 million shares were traded. ABEO stock price reached its highest trading level at $6.95 during the session, while it also had its lowest trading level at $6.78.
Ratios:
Our goal is to gain a better understanding of ABEO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.65 and its Current Ratio is at 6.73. In the meantime, Its Debt-to-Equity ratio is 0.15 whereas as Long-Term Debt/Eq ratio is at 0.11.
On March 05, 2025, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $16.
On July 03, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $15.H.C. Wainwright initiated its Buy rating on July 03, 2024, with a $15 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 14 ’25 when Crombez Eric sold 4,718 shares for $6.93 per share. The transaction valued at 32,683 led to the insider holds 42,427 shares of the business.
Vazzano Joseph Walter sold 15,000 shares of ABEO for $110,358 on Aug 15 ’25. The Chief Financial Officer now owns 462,666 shares after completing the transaction at $7.36 per share. On Aug 15 ’25, another insider, Vazzano Joseph Walter, who serves as the Officer of the company, bought 15,000 shares for $7.36 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABEO now has a Market Capitalization of 350744960 and an Enterprise Value of 149303200. As of this moment, Abeona’s Price-to-Earnings (P/E) ratio for their current fiscal year is 10.84, and their Forward P/E ratio for the next fiscal year is 40.63. For the stock, the TTM Price-to-Sale (P/S) ratio is 876.85 while its Price-to-Book (P/B) ratio in mrq is 2.14. Its current Enterprise Value per Revenue stands at 373.258 whereas that against EBITDA is -2.061.
Stock Price History:
The Beta on a monthly basis for ABEO is 1.66, which has changed by 0.3053435 over the last 52 weeks, in comparison to a change of 0.14064062 over the same period for the S&P500. Over the past 52 weeks, ABEO has reached a high of $7.54, while it has fallen to a 52-week low of $3.93. The 50-Day Moving Average of the stock is 9.10%, while the 200-Day Moving Average is calculated to be 17.95%.
Shares Statistics:
The stock has traded on average 951.36K shares per day over the past 3-months and 799880 shares per day over the last 10 days, according to various share statistics. A total of 51.25M shares are outstanding, with a floating share count of 45.58M. Insiders hold about 11.10% of the company’s shares, while institutions hold 69.24% stake in the company. Shares short for ABEO as of 1753920000 were 8416383 with a Short Ratio of 8.85, compared to 1751241600 on 8294959. Therefore, it implies a Short% of Shares Outstanding of 8416383 and a Short% of Float of 17.61.
Earnings Estimates
The dynamic stock of Abeona Therapeutics Inc (ABEO) is currently being evaluated by a team of 4.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.05 and low estimates of -$0.27.
Analysts are recommending an EPS of between $1.15 and -$1.45 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is -$0.08, with 4.0 analysts recommending between $0.15 and -$0.47.
Revenue Estimates
For the next quarter, 7 analysts are estimating revenue of $21.65M. There is a high estimate of $27.18M for the next quarter, whereas the lowest estimate is $12M.
Based on 7 analysts’ estimates, the company’s revenue will be $116.68M in the next fiscal year. The high estimate is $140.3M and the low estimate is $96.1M.
